{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:06:53Z","timestamp":1788264413119,"version":"build-2803163510"},"reference-count":44,"publisher":"Center for Academic Publications Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nutr Sci Vitaminol","JNSV"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3177\/jnsv.60.122","type":"journal-article","created":{"date-parts":[[2014,6,30]],"date-time":"2014-06-30T00:00:21Z","timestamp":1404086421000},"page":"122-128","source":"Crossref","is-referenced-by-count":35,"title":["Resveratrol Reduces the Hypoxia-Induced Resistance to Doxorubicin in Breast Cancer Cells"],"prefix":"10.3177","volume":"60","author":[{"given":"Takakazu","family":"MITANI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"ITO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"HARADA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"NAKANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"INUI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"ASHIDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"YAMAJI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1759","reference":[{"key":"1","unstructured":"1) Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. 2007. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99: 1152-1161."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Pouysségur J, Dayan F, Mazure NM. 2006. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.","DOI":"10.1038\/nature04871"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Trédan O, Galmarini CM, Patel K, Tannock IF. 2007. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454.","DOI":"10.1093\/jnci\/djm135"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kaur M, Agarwal C, Agarwal R. 2009. Anticancer and cancer chemopreventive potential of grape seed extract and other grape-based products. J Nutr 139: 1806S-1812S.","DOI":"10.3945\/jn.109.106864"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Li Y, Tollefsbol TO. 2010. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem 17: 2141-2151.","DOI":"10.2174\/092986710791299966"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Olaku O, White JD. 2011. Herbal therapy use by cancer patients: a literature review on case reports. Eur J Cancer 47: 508-514.","DOI":"10.1016\/j.ejca.2010.11.018"},{"key":"7","unstructured":"7) Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. 2004. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem 52: 4713-4719."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Tsai SH, Lin-Shiau SY, Lin JK. 1999. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol 126: 673-680.","DOI":"10.1038\/sj.bjp.0702357"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Frémont L, Belguendouz L, Delpal S. 1999. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci 64: 2511-2521.","DOI":"10.1016\/S0024-3205(99)00209-X"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Leifert WR, Abeywardena MY. 2008. Cardioprotective actions of grape polyphenols. Nutr Res 28: 729-737.","DOI":"10.1016\/j.nutres.2008.08.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH. 2010. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554-563.","DOI":"10.2337\/db09-0482"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Filomeni G, Graziani I, Rotilio G, Ciriolo MR. 2007. trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr 2: 295-305.","DOI":"10.1007\/s12263-007-0059-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Osman AM, Bayoumi HM, Al-Harthi SE, Damanhouri ZA, Elshal MF. 2012. Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int 12: 47.","DOI":"10.1186\/1475-2867-12-47"},{"key":"14","unstructured":"14) Ito Y, Mitani T, Harada N, Isayama A, Tanimori S, Yakenaka S, Nakano Y, Inui H, Yamaji R. 2013. Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4′-amino-3,5-dihydroxy-trans-stilbene. J Nutr Sci Vitaminol 59: 358-364."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Gonzalez-Covarrubias V, Ghosh D, Lakhman SS, Pendyala L, Blanco JG. 2007. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab Dispos 35: 973-980.","DOI":"10.1124\/dmd.107.014779"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Bateman RL, Rauh D, Tavshanjian B, Shokat KM. 2008. Human carbonyl reductase 1 is an S-nitrosoglutathione reductase. J Biol Chem 283: 35756-35762.","DOI":"10.1074\/jbc.M807125200"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Bains OS, Karkling MJ, Grigliatti TA, Reid RE, Riggs KW. 2009. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos 37: 1107-1114.","DOI":"10.1124\/dmd.108.024711"},{"key":"18","unstructured":"18) Lopez M. 2006. Anthracyclines in the adjuvant treatment of breast carcinoma: thirty years later. Clin Ter 157: 165-177."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J. 2007. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46: 474-481.","DOI":"10.1016\/j.jhep.2006.10.020"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, Wojnowski L. 2008. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36: 2113-2120.","DOI":"10.1124\/dmd.108.022251"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) López de Cerain A, Marín A, Idoate MA, Tuñón MT, Bello J. 1999. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer 35: 320-324.","DOI":"10.1016\/S0959-8049(98)00372-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Tak E, Lee S, Lee J, Rashid MA, Kim YW, Park JH, Park WS, Shokat KM, Ha J, Kim SS. 2011. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol 54: 328-339.","DOI":"10.1016\/j.jhep.2010.06.045"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Paul S, Mizuno CS, Lee HJ, Zheng X, Chajkowisk S, Rimoldi JM, Conney A, Suh N, Rimando AM. 2010. In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer. Eur J Med Chem 45: 3702-3708.","DOI":"10.1016\/j.ejmech.2010.05.019"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Mitani T, Yamaji R, Higashimura Y, Harada N, Nakano Y, Inui H. 2011. Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1α in a low androgen environment. J Steroid Biochem Mol Biol 123: 58-64.","DOI":"10.1016\/j.jsbmb.2010.10.009"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Mathew A, Mathur SK, Morimoto RI. 1998. Heat shock response and protein degradation: regulation of HSF2 by the ubiquitin-proteasome pathway. Mol Cell Biol 18: 5091-5098.","DOI":"10.1128\/MCB.18.9.5091"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kartner N, Riordan JR, Ling V. 1983. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285-1288.","DOI":"10.1126\/science.6137059"},{"key":"27","unstructured":"27) Gavelová M, Hladíková J, Vildová L, Novotná R, Vondrácek J, Krcmár P, Machala M, Skálová L. 2008. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem Biol Interact 176: 9-18."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM. 2012. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer 12: 381.","DOI":"10.1186\/1471-2407-12-381"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, Wojnowski L. 2008. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36: 2113-2120.","DOI":"10.1124\/dmd.108.022251"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW. 2009. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 332: 755-763.","DOI":"10.1124\/jpet.109.160614"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Martin HJ, Breyer-Pfaff U, Wsol V, Venz S, Block S, Maser E. 2006. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 34: 464-470.","DOI":"10.1124\/dmd.105.007971"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Bains OS, Grigliatti TA, Reid RE, Riggs KW. 2010. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther 335: 533-545.","DOI":"10.1124\/jpet.110.173179"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore M, Ratnam K, Palackal N. 2001. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Mol Cell Endocrinol 171: 137-149.","DOI":"10.1016\/S0303-7207(00)00426-3"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Du GJ, Song ZH, Lin HH, Han XF, Zhang S, Yang YM. 2008. Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells. Biochem Biophys Res Commun 372: 497-502.","DOI":"10.1016\/j.bbrc.2008.05.080"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Park SW, Cho CS, Jun HO, Ryu NH, Kim JH, Yu YS, Kim JS, Kim JH. 2012. Anti-angiogenic effect of luteolin on retinal neovascularization via blockade of reactive oxygen species production. Invest Ophthalmol Vis Sci 53: 7718-7726.","DOI":"10.1167\/iovs.11-8790"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Du G, Lin H, Wang M, Zhang S, Wu X, Lu L, Ji L, Yu L. 2010. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. Cancer Chemother Pharmacol 65: 277-287.","DOI":"10.1007\/s00280-009-1032-7"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Lee DH, Lee YJ. 2008. Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem 105: 546-553.","DOI":"10.1002\/jcb.21851"},{"key":"38","unstructured":"38) Cao Z, Fang J, Xia C, Shi X, Jiang BH. 2004. trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 10: 5253-5263."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. 2005. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4: 1465-1474.","DOI":"10.1158\/1535-7163.MCT-05-0198"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Iguchi K, Toyama T, Ito T, Shakui T, Usui S, Oyama M, Iinuma M, Hirano K. 2012. Antiandrogenic activity of resveratrol analogs in prostate cancer LNCaP cells. J Androl 33: 1208-1215.","DOI":"10.2164\/jandrol.112.016782"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, Forti L, Stivala LA, Iacopetta D, Dolce V, Andò S, Pezzi V, Maggilini M. 2009. Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol Nutr Food Res 53: 845-858.","DOI":"10.1002\/mnfr.200800331"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.","DOI":"10.1124\/pr.56.2.6"},{"key":"43","unstructured":"43) Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. 2003. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63: 6602-6606."},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Gu J, Song ZP, Gui DM, Hu W, Chen YG, Zhang DD. 2012. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol 4: 341-349.","DOI":"10.1007\/s12012-012-9178-7"}],"container-title":["Journal of Nutritional Science and Vitaminology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T01:53:05Z","timestamp":1565574785000},"score":1,"resource":{"primary":{"URL":"http:\/\/jlc.jst.go.jp\/DN\/JST.JSTAGE\/jnsv\/60.122?lang=en&from=CrossRef&type=abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3177\/jnsv.60.122","relation":{},"ISSN":["0301-4800","1881-7742"],"issn-type":[{"value":"0301-4800","type":"print"},{"value":"1881-7742","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}